IQVIA (IQV)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$263.79+0.46%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
Research Workspace
Put IQV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS near $12.7 in 2026: Diluted EPS: $2.10 per share.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 18%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, guidance credibility, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIQVIA's R&D Solutions backlog has to keep compounding to justify the price. Revenue grew 8.0% year over year in the latest quarter. The company beat its earnings estimate by 13.6%. It trades at 22 times earnings versus a 36 times peer median. The price reflects less growth than we forecast. A guidance cut would hit credibility and the number. Our model puts the next-quarter miss near 14%. Peer multiples imply a price about 19% above where it trades. The thesis is on watch.
Trailing returns as of 2026-11-04. IQV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering IQV (as of Nov 2026).
Based on 10 Wall Street analysts offering 12-month price targets for IQV in the last 4 months.
Continue this research
Compare IQV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IQV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put IQV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Reaffirm and raise full-year 2026 revenue and earnings guidance
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $263.79
The last 12 months of price, then the range of analyst 12-month targets from today’s $263.79.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
2026 revenue and EPS guidance plus strong clinical bookings support growth and R&D demand.
Threatens: Reaffirm full-year 2026 revenue guidance
Q1 growth may impact full-year revenue guidance.
Advances: Expand R&D Solutions backlog and net new bookings
Launch supports expansion of R&D Solutions backlog.
Advances: Expand R&D Solutions backlog and net new bookings
Positive coverage supports bookings outlook and growth objectives.
Advances: Reaffirm and raise full-year 2026 revenue and earnings guidance
Higher price target indicates confidence in revenue growth.
Advances: Increase share repurchase authorization and execute buybacks
Senior notes offering supports capital allocation strategy.
Threatens: Increase share repurchase authorization and execute buybacks
Debt issuance may limit future share repurchase capacity.
Advances: Expand R&D Solutions backlog and net new bookings
Enhances R&D Solutions backlog and net new bookings potential.
